Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poverty and suicide research in low- and middle-income countries: systematic mapping of literature published in English and a proposed research agenda.

Global mental health (Cambridge, England)·2017
Same author

A big cover-up.

Heart (British Cardiac Society)·2009
Same author

Testosterone and coronary artery disease.

Frontiers of hormone research·2008
Same author

Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarction.

American journal of hypertension·2000
Same author

Public consultation. Centre of attention.

The Health service journal·2000
Same author

[11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis.

Neurology·1999
Same journal

What Is Hidden Behind Growth Hormone Deficiency? The Neuroradiologist's Perspective.

Frontiers of hormone research·2024
Same journal

Fugitive Acromegaly: A Historical, Clinical, and Translational Perspective.

Frontiers of hormone research·2024
Same journal

Perioperative Mobility Assessment of Acromegalic Patients Undergoing Endoscopic Endonasal Resection of Pituitary Adenomas Using Digital Phenotyping.

Frontiers of hormone research·2024
Same journal

Treatment with Long-Acting Somatostatin Analogues in Patients with Acromegaly: When and How.

Frontiers of hormone research·2024
Same journal

Bone, Metabolic and Mental Detrimental Effects of GHD: Reasons Underlying Replacement Therapy in Adults.

Frontiers of hormone research·2024
Same journal

Pituitary Acrogigantism: From the Past to the Future.

Frontiers of hormone research·2024
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Testosterone in chronic heart failure.

C Malkin1, T Jones, K Channer

  • 1Department of Cardiology, Royal Hallamshire Hospital, Sheffield, UK.

Frontiers of Hormone Research
|November 18, 2008
PubMed
Summary
This summary is machine-generated.

Testosterone replacement therapy may benefit chronic heart failure patients, contrary to common belief. Evidence suggests testosterone treatment can help manage disordered metabolism and androgen imbalance in heart failure.

More Related Videos

A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

Related Experiment Videos

Last Updated: Jun 28, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Chronic heart failure (CHF) is a complex syndrome involving cardiac dysfunction and neurohormonal imbalance.
  • Testosterone therapy is often perceived as detrimental to cardiovascular health, particularly in males.
  • Misconceptions link male cardiovascular disease prevalence to endogenous testosterone levels.

Purpose of the Study:

  • To review existing evidence on the cardiovascular effects of endogenous and therapeutic testosterone.
  • To evaluate the potential benefits of testosterone replacement therapy (TRT) in chronic heart failure patients.
  • To address the misconception regarding testosterone's role in cardiovascular disease.

Main Methods:

  • Literature review of published studies on testosterone's effects on the cardiovascular system.
  • Analysis of evidence focusing on patients with chronic heart failure.
  • Examination of metabolic and neurohormonal changes in heart failure and their relation to androgens.

Main Results:

  • Developing evidence suggests testosterone treatment may be beneficial for chronic heart failure.
  • CHF is characterized by progressive metabolic dysfunction and androgen imbalance.
  • Testosterone's role in cardiovascular health requires re-evaluation, especially in specific patient populations.

Conclusions:

  • Testosterone replacement therapy shows promise as a treatment for chronic heart failure.
  • Patients with chronic heart failure may particularly benefit from TRT due to their specific metabolic profile.
  • Further research is warranted to clarify testosterone's therapeutic potential in cardiovascular conditions.